Connect with us

Artificial Intelligence

Progenics Pharmaceuticals Announces Presentation at the 2020 SNMMI Mid-Winter Meeting

GlobeNewswire

Published

on

NEW YORK, Jan. 16, 2020 (GLOBE NEWSWIRE) — Progenics Pharmaceuticals, Inc. (Nasdaq:PGNX), an oncology company developing innovative targeted medicines and artificial intelligence to find, fight and follow cancer, today announced that an abstract highlighting data from its PSMA AI program has been selected for a moderated poster presentation at the 2020 Society for Nuclear and Molecular Medicine (SNMMI) Mid-Winter Meeting, which will be held from January 23 – 25, 2020 in Tampa, FL.  

Date & Time: January 23, 2020 from 12:15 p.m. to 1:15 p.m. Eastern Time
Title:
Deep Learning-Enabled Automated Hotspot Detection from 18F-DCFPyL (PyL-PSMA) PET/CT in Metastatic Prostate Cancer

About PyL™ for PET Imaging of Prostate Cancer
PyL (also known as 18F-DCFPyL) is a fluorinated PSMA-targeted positron emission tomography (“PET”) imaging agent that enables visualization of both bone and soft tissue metastases to determine the presence or absence of recurrent and/or metastatic prostate cancer.

About PROGENICS

Progenics is an oncology company focused on the development and commercialization of innovative targeted medicines and artificial intelligence to find, fight and follow cancer, including: therapeutic agents designed to treat cancer (AZEDRA®, 1095, and PSMA TTC); prostate-specific membrane antigen (“PSMA”) targeted imaging agents for prostate cancer (PyL™ and 1404); and imaging analysis technology (aBSI and PSMA AI). Progenics has three commercial products, AZEDRA, for the treatment of patients with unresectable, locally advanced or metastatic pheochromocytoma or paraganglioma (rare neuroendocrine tumors of neural crest origin) who require systemic anticancer therapy; and oral and subcutaneous formulations of RELISTOR® (methylnaltrexone bromide) for the treatment of opioid-induced constipation, which are partnered with Bausch Health Companies Inc.

Forward Looking Statements
This press release contains projections and other “forward-looking statements” regarding future events. Statements contained in this communication that refer to Progenics’ estimated or anticipated future results or other non-historical facts are forward-looking statements that reflect Progenics’ current perspective of existing trends and information as of the date of this communication and include statements regarding Progenics’ strategic and operational plans and delivering value for shareholders. Forward looking statements generally will be accompanied by words such as “anticipate,” “believe,” “plan,” “could,” “should,” “estimate,” “expect,” “forecast,” “outlook,” “guidance,” “intend,” “may,” “might,” “will,” “possible,” “potential,” “predict,” “project,” or other similar words, phrases or expressions. Such statements are predictions only and are subject to risks and uncertainties that could cause actual events or results to differ materially. These risks and uncertainties include, among others: risks associated with the proposed merger transaction with Lantheus Holdings, Inc.; market acceptance for approved products; the risk that the commercial launch of AZEDRA may not meet revenue and income expectations; the cost, timing and unpredictability of results of clinical trials and other development activities and collaborations; the unpredictability of the duration and results of regulatory review of New Drug Applications (NDA) and Investigational NDAs; the inherent uncertainty of outcomes in the intellectual property disputes such as the dispute with the University of Heidelberg regarding PSMA-617; our ability to successfully develop and commercialize products that incorporate licensed intellectual property; the effectiveness of the efforts of our partners to market and sell products on which we collaborate and the royalty revenue generated thereby; generic and other competition; the possible impairment of, inability to obtain and costs of obtaining intellectual property rights; possible product safety or efficacy concerns, general business, financial, regulatory and accounting matters, litigation and other risks; and risks related to changes in the composition of our Board of Directors following the delivery of shareholder consents in response to the recent consent solicitation conducted by one of our shareholders. More information concerning Progenics and such risks and uncertainties is available on its website, and in its press releases and reports it files with the Securities and Exchange Commission (the “SEC”), including those risk factors included in its Annual Report on Form 10-K for the year ended December 31, 2018, as updated in its subsequent Quarterly Reports on Form 10-Q. Progenics is providing the information in this press release as of its date and, except as expressly required by law, Progenics disclaims any intent or obligation to update or revise any forward-looking statements, whether as a result of new information, future events or circumstances or otherwise.

Additional information concerning Progenics and its business may be available in press releases or other public announcements and public filings made after this press release. For more information, please visit www.progenics.com. Information on or accessed through our website or social media sites is not included in the company’s SEC filings.

Contact
Melissa Downs
Investor Relations
(646) 975-2533
mdowns@progenics.com

GlobeNewswire is one of the world's largest newswire distribution networks, specializing in the delivery of corporate press releases financial disclosures and multimedia content to the media, investment community, individual investors and the general public.

Artificial Intelligence

Aidéo Technologies Launches Free Use of AI-Powered Automated CPT and Diagnosis Coding During the US Response to COVID-19

GlobeNewswire

Published

on

MELBOURNE, Fla., April 01, 2020 (GLOBE NEWSWIRE) — Aidéo Technologies – a leader in AI-enabled automation technology for the healthcare industry – announced today that it will allow healthcare organizations and revenue cycle management companies to utilize its AI enabled medical coding engine Gemini AutoCode™ free of charge in response to COVID-19.
COVID-19 has disrupted the global revenue cycle management workforce and created challenges for organizations lacking a secure infrastructure to allow employees to work from home while under shelter-in-place mandates. As a by-product, physician practice and hospital revenue are negatively impacted.There is a growing concern over security of US patient data as many companies cannot meet security requirements in a work from home environment. “Aidéo Technologies wants to help the US Healthcare Delivery System remain financially viable during this national crisis,” said Rob Gontarek, the President and CEO of Aidéo Technologies. “We are making our technology platform available at no cost for the duration of the crisis to affected providers and revenue cycle management companies. Organizations can gain immediate access to a secure solution to the disruption in the global workforce.” The business continuity of medical groups and hospitals can be maintained using the machine learning models for medical coding through Gemini AutoCode™.Gemini AutoCode™ uses AI, a proprietary Natural Language Processing engine, and machine learning to interpret structured and unstructured clinical data. The application assigns the appropriate procedure and diagnosis codes, with no human intervention required. Gemini AutoCode™ easily integrates with electronic medical records and can accurately interpret and code over forty-thousand clinical encounters per hour.It is expected that COVID-19 will have a lasting impact on the US Healthcare Delivery System and the machine learning of Gemini AutoCode™ will offer relief to entities impacted by the crisis. For more information, please visit www.aideo-tech.com/howcanwehelp?About Aidéo Technologies
Aidéo Technologies (www.aideo-tech.com) provides software automation tools using artificial intelligence, robotics, and machine learning to the healthcare industry. Established in 2009, the company has development centers in Melbourne, Florida, and Silicon Valley. Aidéo is a portfolio company of Avtar Investments (www.avtarinvestments.com), a private family office investment firm focused on disruptive technology in healthcare.
Contact:
Laura Krejca
Senior Director, Client Service
laura.krejca@aideo-tech.com

Continue Reading

Artificial Intelligence

2nd Gen AMD EPYC™ Processors Power New IBM Cloud Bare Metal Servers

GlobeNewswire

Published

on

SANTA CLARA, Calif., April 01, 2020 (GLOBE NEWSWIRE) — Today, AMD announced that IBM Cloud is enhancing its global infrastructure with 2nd Gen AMD EPYC™ processors to power its latest bare metal servers. With the addition of the AMD EPYC 7642 processor to its cloud portfolio, IBM is engineered to deliver increased computing performance in its bare metal offerings. Available now, these new bare metal servers are the first 2nd Gen AMD EPYC™ based offering from IBM Cloud and are focused on the computing power and performance required to accelerate modern workloads like data analytics, electronic design automation, artificial intelligence and virtualized and containerized workloads.
“2nd Gen AMD EPYC processors deliver where it counts for cloud providers, providing the cores, scalability and throughput for critical workloads,” said Forrest Norrod, senior vice president and general manager, Data Center and Embedded Solutions, AMD. “We are extremely excited to extend the advantages of 2nd Gen AMD EPYC processors to new bare metal offerings at IBM Cloud, helping customers tackle today’s compute-intensive workloads.”“We are thrilled to launch new IBM Cloud offerings powered by the 2nd Gen AMD EPYC CPUs,” says Satinder Sethi, GM, IBM Cloud Infrastructure Services. “With these new processors, we can offer IBM Cloud clients greater choice and flexibility to select the platform that is best suited to meet the needs of today’s most demanding workloads. We look forward to continuing to deliver new innovations and value to our clients in the future.”The AMD EPYC 7642 based, dual socket bare metal server offering at IBM Cloud includes:96 CPU cores per platformBase clock frequency of 2.3GHz with a Max Boost up to 3.3GHzi8 memory channels per socket for superior memory bandwidthUp to 4TB memory configuration supportUp to 24 local storage drivesOS choices of RHEL, CentOS, Ubuntu, MS ServerMonthly, pay-as-you-use billingOrderable via the global IBM Cloud Catalogue, API, or CLIThe bare metal servers are being made available in IBM Data Centers across the North America, Europe, and Asia Pacific regions. The AMD EPYC 7642 based servers can be ordered via the IBM Cloud global catalogue portal, API or CLI and consumed in a monthly pay-as-you-use model. Visit IBM Cloud to start building a bare metal server configuration with 2nd Gen AMD EPYC processors.Supporting ResourcesLearn more about IBM Cloud Bare Metal ServersRead more at the IBM BlogLearn more about the AMD 2nd Gen EPYCTM ProcessorBecome a fan of AMD on FacebookFollow AMD on TwitterAbout AMD
For more than 50 years AMD has driven innovation in high-performance computing, graphics and visualization technologies ― the building blocks for gaming, immersive platforms and the datacenter. Hundreds of millions of consumers, leading Fortune 500 businesses and cutting-edge scientific research facilities around the world rely on AMD technology daily to improve how they live, work and play. AMD employees around the world are focused on building great products that push the boundaries of what is possible. For more information about how AMD is enabling today and inspiring tomorrow, visit the AMD (NASDAQ: AMD) website, blog, Facebook and Twitter pages.
AMD, the AMD Arrow logo, EPYC, and combinations thereof, are trademarks of Advanced Micro Devices, Inc. Other names are for informational purposes only and may be trademarks of their respective owners.i Max boost for AMD EPYC processors is the maximum frequency achievable by any single core on the processor under normal operating conditions for server systems. EPYC-18 
Contact:
Aaron Grabein
AMD Communications
(512) 602-8950 Laura Graves
AMD Investor Relations
(408) 749-5467

Continue Reading

Artificial Intelligence

Predictive Oncology Reports 2019 Full-year Financial Results

GlobeNewswire

Published

on

MINNEAPOLIS, April 01, 2020 (GLOBE NEWSWIRE) — Predictive Oncology Inc. (NASDAQ: POAI) (“Predictive Oncology” or “the Company”), a knowledge-driven company focused on applying artificial intelligence (“AI”) to personalized medicine and drug discovery, today reported financial results for its full year ended December 31, 2019, as well as select corporate highlights.Q4 HighlightsSecured $15.0 Million equity line with Oasis Capital, LLCNew subsidiary Helomics reached milestone sequencing tumor cases in partnership with UPMC MageeSubsidiary Skyline Medical completed largest STREAMWAY™ System order to a single hospital in the Company’s historyLaunched CancerQuest 2020 initiative, with ovarian cancer initial targetFull-Year 2019 Results – 2019 vs. 2018Revenues were $1.4 million, flat year on year relative to $1.4 million in 2018Net loss was $19.7 million versus $10.1 million in 2018, owing in part to Helomics merger expenses, goodwill impairment, and other extraneous expenses related to the transaction.Bob Myers, CFO of Predictive Oncology, stated, “2019 was not without its challenges for the entire healthcare technology industry, yet we continued to execute on our business model, making a synergistic acquisition and shoring up our balance sheet via a new $15.0 million equity line from Oasis Capital. Our STREAMWAY line has maintained strong disposable product sales and we continue to sell the STREAMWAY System.”“We continue to be very excited about the revenue and monetization prospects for our precision medicine business, which will allow us to be at the forefront of developing the artificial intelligence required to combat a variety of ailments, as well as our revolutionary STREAMWAY clinical waste disposal products,” stated Dr. Carl Schwartz, CEO and Director. “We will continue to execute upon our comprehensive strategy to deliver long-term profitable growth and innovation while concentrating our efforts and resources on our recently acquired Helomics business.”“Building on the successes in 2019, we have recently announced the launch of our CancerQuest 2020 initiative, and we expect Helomics’ first AI-driven predictive model of ovarian cancer to be ready for initial commercialization in revenue generating projects with Pharma in Q2-2020,” Dr. Schwartz added. “Furthermore, we have signed a Letter of Intent to acquire Quantitative Medicine, a biomedical analytics and computational biology company. Against this backdrop, we believe that Predictive Oncology will continue to be a pioneer within the fields of biomarker discovery and precision therapies going forward.”FULL-YEAR 2019 RESULTSRevenues were $1.4 million, consistent with 2018. Revenues in both years were primarily driven through the sale of Predictive Oncology’s proprietary STREAMWAY units, of which 43 units and 41 units were sold, respectively, in each of 2019 and 2018. Gross margins remained strong, declining slightly to 62% in 2019, from 71% in 2018, largely due to the increase in costs following the consolidation of the Helomics acquisition on April 4, 2019. However, exclusive of Helomics, the cost of sales related to the sale of STREAMWAY products was comparable on a year-on-year basis.Net losses for 2019 totaled $19.7 million versus $10.1 million in 2018. General & administrative expenses rose 111% to nearly $9.8 million in 2019 as a result of extraneous expenses and initial costs related to the Helomics merger.  In addition, Predictive Oncology recognized a credit loss of $1.0 million in notes receivable from CytoBioscience (now operating as InventaBioTech). Operational expenses also rose to $3.0 million, compared to $1.8 million in 2018. Net loss in 2019 reflected impairment charges of $8.1 million on goodwill related to the Helomics merger and $0.8 million on intangibles, versus no impairment charges in 2018.Separately, the Company benefited from a gain of $6.1 million as a result of the revaluation of the equity method investment recorded post the initial 25% purchase of Helomics, following the merger and consolidation of Helomics effective April 4, 2019. Predictive Oncology also incurred other expenses of $4.0 million in 2019 compared to only $441,000 in 2018, primarily due to an increase in interest expense, payment penalties, amortization of original issue discounts and a loss on debt extinguishment related to our notes payable.OUTLOOKGoing forward, management intends to focus its resources on the Helomics and TumorGenesis divisions and the Company’s primary mission of applying artificial intelligence to precision medicine, drug discovery and the mediums used to replace rats and mice in preliminary cancer studies. Predictive Oncology had previously reported in December 2019 that it had received several indications of interest for the possible acquisition of its Skyline Medical division (which owns and markets the Company’s proprietary STREAMWAY System) no further action has resulted from these indications, and today management reaffirms that it is focusing the majority of its resources on maximizing opportunities within the Company’s precision medicine business.About Predictive Oncology Inc.Predictive Oncology (Nasdaq: POAI) operates through three segments (Domestic, International and Helomics), which contain four subsidiaries; Helomics, TumorGenesis, Skyline Medical and Skyline Europe. Helomics applies artificial intelligence to its rich data gathered from patient tumors to both personalize cancer therapies for patients and drive the development of new targeted therapies in collaborations with pharmaceutical companies. Helomics’ CLIA-certified lab provides clinical testing that assists oncologists in individualizing patient treatment decisions, by providing an evidence-based roadmap for therapy. In addition to its proprietary precision oncology platform, Helomics offers boutique CRO services that leverage its TruTumor™, patient-derived tumor models coupled to a wide range of multi-omics assays (genomics, proteomics and biochemical), and an AI-powered proprietary bioinformatics platform to provide a tailored solution to its clients’ specific needs. Predictive Oncology’s TumorGenesis subsidiary is developing a new rapid approach to growing tumors in the laboratory, which essentially “fools” cancer cells into thinking they are still growing inside a patient. Its proprietary Oncology Discovery Technology Platform kits will assist researchers and clinicians to identify which cancer cells bind to specific biomarkers. Once the biomarkers are identified they can be used in TumorGenesis’ Oncology Capture Technology Platforms which isolate and help categorize an individual patient’s heterogeneous tumor samples to enable the development of patient specific treatment options. Helomics and TumorGenesis are focused on ovarian cancer. Predictive Oncology’s Skyline Medical division markets its patented and FDA cleared STREAMWAY System, which automates the collection, measurement and disposal of waste fluid, including blood, irrigation fluid and others, within a medical facility, through both domestic and international divisions. The company has achieved sales in five of the seven continents through both direct sales and distributor partners. For more information, please visit www.predictive-oncology.com.Forward-looking StatementsPortions of the narrative set for this this document that are not statements of historical or current facts are forward-looking statements, in particular, the commercial outlook provided above. Our actual future performance may materially differ from that contemplated by the forward-looking statements as a result of a variety of factors.These factors include, in addition to those mentioned elsewhere herein: 
We may not be able to continue operating without additional financing;Current negative operating cash flows;The terms of any further financing, which may be highly dilutive and may include onerous terms;Risks related to the 2019 merger with Helomics including; 1) significant goodwill could result in further impairment; 2) possible failure to realize anticipated benefits of the merger; 3) costs associated with the merger may be higher than expected; 4) the merger may result in the disruption of our existing businesses; and 5) distraction of management and diversion of resources;Risks related to our partnerships with other companies, including the need to negotiate the definitive agreements; possible failure to realize anticipated benefits of these partnerships; and costs of providing funding to our partner companies, which may never be repaid or provide anticipated returns;Risks related to the transaction with Quantitative Medicine including: 1) completion of the transaction; 2) possible failure to realize anticipated benefits of the merger; 3) costs associated with the merger may be higher than expected; 4) the merger may result in the disruption of our existing businesses; and 5) distraction of management and diversion of resources;Risk that we will be unable to complete the transaction with InventaBio Tech;Risk that we will be unable to protect our intellectual property or claims that we are infringing on others’ intellectual property;The impact of competition;Acquisition and maintenance of any necessary regulatory clearances applicable to applications of our technology;Inability to attract or retain qualified senior management personnel, including sales and marketing personnel;Risk that we never become profitable if our product is not accepted by potential customers;Possible impact of government regulation and scrutiny;Unexpected costs and operating deficits, and lower than expected sales and revenues, if any;Adverse results of any legal proceedings;The volatility of our operating results and financial condition, and,Other specific risks that may be alluded to in this report.Contact:
Predictive Oncology, Inc.
Consolidated Balance Sheets

Predictive Oncology, Inc.
Consolidated Statements of Operations

Continue Reading

Trending

Roboticulized is part of PICANTE Media and Events, a leading media and boutique event organizer in the European Union with a monthly reach of +50,000 readers. The official company (PROSHIRT SRL), has been listed for 4 years in a row among the top 3 Advertising and market research agencies in the local Top Business Romania Microcompanies based on the Financial Reports. Roboticulized digests / hand picks the latest news about the AI industry and serves them to you daily.

Contact us: sales@picante.today

Editorial / PR Submissions

© Roboticulized.com 2019 - 2020 - part of PICANTE Media. All rights reserved. Registered in Romania under Proshirt SRL, Company number: 2134306, EU VAT ID: RO21343605. Office address: Blvd. 1 Decembrie 1918 nr.5, Targu Mures, Romania